| Revision as of 23:01, 13 December 2024 editWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits create | Revision as of 05:31, 14 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,738 edits + citationNext edit → | ||
| Line 101: | Line 101: | ||
| }} | }} | ||
| '''Garadacimab''' is an experimental ] under investigation for the treatment of ].<ref name="Andembry EPAR" /> Garadacimab is a humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.<ref>{{cite web | title=Garadacimab (Code C166633) | website=NCI Thesaurus | date=25 November 2024 | url=https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166633 | access-date=13 December 2024}} {{PD-notice}}</ref> | '''Garadacimab''' is an experimental ] under investigation for the treatment of ].<ref name="Andembry EPAR" /> Garadacimab is a humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.<ref>{{cite web | title=Garadacimab (Code C166633) | website=NCI Thesaurus | date=25 November 2024 | url=https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166633 | access-date=13 December 2024}} {{PD-notice}}</ref><ref name="Cohn_2024">{{cite journal | vauthors = Cohn DM, Renné T | title = Targeting factor XIIa for therapeutic interference with hereditary angioedema | journal = Journal of Internal Medicine | volume = 296 | issue = 4 | pages = 311–326 | date = October 2024 | pmid = 39331688 | doi = 10.1111/joim.20008= }}</ref> | ||
| == Society and culture == | == Society and culture == | ||
Revision as of 05:31, 14 December 2024
MedicationPharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Clinical data | |
| Drug class | Bleeding suppressant |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Garadacimab is an experimental monoclonal antibody under investigation for the treatment of hereditary angioedema. Garadacimab is a humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
Society and culture
Legal status
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Andembry, intended for the prevention of recurrent attacks of hereditary angioedema. The applicant for this medicinal product is CSL Behring GmbH.
Garadacimab was designated an orphan medicine by the EMA.
Names
Garadacimab is the international nonproprietary name.
References
- ^ "Andembry EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 13 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Garadacimab (Code C166633)". NCI Thesaurus. 25 November 2024. Retrieved 13 December 2024.
This article incorporates text from this source, which is in the public domain.
- Cohn DM, Renné T (October 2024). "Targeting factor XIIa for therapeutic interference with hereditary angioedema". Journal of Internal Medicine. 296 (4): 311–326. doi:10.1111/joim.20008=. PMID 39331688.
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
| Other hematological agents (B06) | |
|---|---|
| Enzymes (B06AA) | |
| Drugs used in hereditary angioedema (B06AC) | |
| Drugs used in sickle cell disease and beta thalassemia (B06AX) | |
| Others | |
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |